# A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.

> **NCT07555392** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bharat Biotech International Limited** · enrollment: 1000 (estimated)

## Conditions studied

- Active Immunisation for Chikungunya Virus Infection

## Interventions

- **BIOLOGICAL:** BBV87 Chikungunya vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07555392
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2026-09-20
- **Final completion:** 2027-08-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07555392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07555392, "A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07555392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*